 SAN JOSE, Calif., March 22, 2021 PRNewswire -- Anixa Biosciences, Inc. NASDAQ: ANIX Anixa or the Company, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 4,285,715 shares of common stock of the Company at a public offering price of 5.25 per share, less underwriting discounts and commissions. 